Involving Oxidoreductase Patents (Class 435/25)
-
Publication number: 20100311133Abstract: An electrode that can generate reduced coenzymes from a desired substrate in multiple stages is provided. An electrode includes a 2-hydroxycarboxylic acid synthase, a 2-oxo acid synthase, and a 2-oxo acid carboxylyase. The electrode includes a 2-oxo acid carboxylyase, which is a decarboxylase, in addition to a 2-hydroxycarboxylic acid synthase and a 2-oxo acid synthase, which are oxidoreductases; therefore, oxidation products having carboxyl groups, reactions of which do not proceed with oxidoreductases, can be decarboxylated and modified into substances with which oxidoreductases can act. Thus, oxidation reactions and decarboxylation reactions can repeatedly proceed with respect to desired substrates, and large quantities of reduced coenzymes can be generated thereby.Type: ApplicationFiled: December 4, 2008Publication date: December 9, 2010Applicants: SONY CORPORATION, AMANO ENZYME INC.Inventors: Yuichi Tokita, Hideki Sakai, Toshiyuki Sugiura, Chinatsu Goto, Tetsuya Takahashi
-
Publication number: 20100304415Abstract: A high performance liquid chromatography method to routinely and reproducibly detect and quantitate metal complexes is provided. The metal complexes used in the method of the invention can be different metal complexes, or they can be stereoisomers of the same metal complexes. The high performance liquid chromatography method of the present invention is suitable for the separation of diastereomers of the same metal complexes. Also provided is a chiral high performance liquid chromatography method to separate enantiomers of metal complexes. Superoxide dismutase mimetic compounds are also provided.Type: ApplicationFiled: May 25, 2010Publication date: December 2, 2010Inventors: Urszula J. Slomczynska, Bobby N. Trawick, Dennis P. Riley, Arati Naik
-
Publication number: 20100305119Abstract: A method of treating an anthrax infection wherein a compound of formula I wherein R1 and R2 represent, independently of one another unsubstituted or specifically substituted C1-4alkoxy; and R3 represents hydrogen; cyano; unsubstituted or specifically substituted C1-6alkyl; C3-6cycloalkyl; C2-6alkenyl; C7-18bicyclyl; aryl, aryl-C1-4alkyl, aryl-Q-C1-4alkyl heteroaryl, heterocyclyl or heterocyclyl-C1-6alkyl, wherein aryl denotes a mono- or poly-nucleous group with 6 to 14 ring carbon atoms; heterocyclyl denotes a 4- to 6-membered non-aromatic heterocyclic group comprising 1 to 3, nitrogen, oxygen and/or sulfur atoms; heteroaryl denotes a mono- or polynuclear heteroaromatic group consisting 5- and/or 6-membered rings and comprising 5 to 13 carbon atoms and 1 to 4, nitrogen, oxygen and/or sulfur atoms; and Q means —SO— or —SO2—; or a pharmaceutically acceptable salt, solvate or hydrate or a prodrug thereof; is administered to said subject in a quantity effective to inhibit, suppress, or expel an anthrax infType: ApplicationFiled: September 25, 2006Publication date: December 2, 2010Inventors: Jurg Dreier, William Barrow, Esther Barrow
-
Publication number: 20100305070Abstract: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.Type: ApplicationFiled: April 30, 2010Publication date: December 2, 2010Applicant: The University Court of the University of DundeeInventors: Steven Albert Everett, Saraj Ulhaq
-
Publication number: 20100304416Abstract: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).Type: ApplicationFiled: June 16, 2010Publication date: December 2, 2010Inventors: Jack PUYMIRAT, Daniel Beaulieu, Pierre Chapdelaine
-
Patent number: 7838263Abstract: This invention relates to polynucleotide sequences encoding a gene that can confer resistance to at least one herbicide. It further relates to plants and seeds of plants carrying chimeric genes comprising said polynucleotide sequences, which enhance or confer resistance to at least one herbicide, and methods of making said plants and seeds. The invention further presents sequences that can be used as molecular markers that in turn can be used to identify the region of interest in corn lines resulting from new crosses and to quickly and efficiently select the best lines for breeding strategies by avoiding sensitive lines. Methods of identifying a plant with an Nsf1 locus using molecular markers are described.Type: GrantFiled: December 27, 2007Date of Patent: November 23, 2010Assignee: E. I. du Pont de Nemours and CompanyInventors: Thao Dam, Anthony D. Guida, Jr., Christine B. Hazel, Bailin Li, Mark E. Williams
-
Patent number: 7838262Abstract: The present invention provides an in vitro method for quantifying exposure to psychological stress which relies on measuring the retained ability of neutrophils, preferably neutrophils in a whole blood sample, to exhibit challenge-induced superoxide anion production. Using such methodology, coping capacity of individuals for particular psychological stressors may be assessed.Type: GrantFiled: November 5, 2003Date of Patent: November 23, 2010Assignee: Oxford Medistress LimitedInventors: Rubina Mian, David Whyte MacDonald
-
Patent number: 7833744Abstract: The present invention relates, generally to a method of determining and assessing cytochrome P450 2C19-related (CYP2Cl9) metabolic capacity in an individual mammalian subject via a breath assay, by determining the relative amount of 13CO2 exhaled by the subject upon intravenous or oral administration of a 13C-labeled CYP2C19 substrate compound. The present invention is useful as a non-invasive, in vivo assay for evaluating CYP2C19 enzyme activity in a subject using the metabolite 13CO2 in expired breath, to phenotype individual subjects and to determine the selection, optimal dosage and timing of drug administration.Type: GrantFiled: August 31, 2007Date of Patent: November 16, 2010Assignee: Cambridge Isotope Laboratories, Inc.Inventors: David A. Flockhart, Zeruesenay Desta, Anil S. Modak, Yasuhisa Kurogi
-
Publication number: 20100285514Abstract: Networks of single-walled carbon nanotubes (SWCNTs) decorated with Au-coated Pd (Au/Pd) nanocubes are employed as electrochemical biosensors that exhibit excellent sensitivity (2.6 mA mM?1 cm?2) and a low estimated detection limit (2.3 nM) at a signal-to-noise ratio of 3 (S/N=3) in the amperometric sensing of hydrogen peroxide. Biofunctionalization of the Au/Pd nanocube-SWCNT biosensor is demonstrated with the selective immobilization of fluorescently labeled streptavidin on the nanocube surfaces via thiol linking. Similarly, glucose oxidase (GOx) is linked to the surface of the nanocubes for amperometric glucose sensing. The exhibited glucose detection limit of 1.3_M (S/N=3) and linear range spanning from 10 ?M to 50 mM substantially surpass other CNT-based biosensors.Type: ApplicationFiled: January 27, 2010Publication date: November 11, 2010Inventors: Jonathan Clay Claussen, Aaron D. Franklin, Timothy S. Fisher, D. Marshall Porterfield
-
Publication number: 20100276325Abstract: An oxygen indicator using an optical absorption spectral change reaction caused by a substrate in the presence of oxygen via an enzymatic catalysis, which comprises an oxygen sensitive solution containing at least a coloring substrate, an oxidoreductase, and a reducing agent capable of reducing the oxidized coloring substrate.Type: ApplicationFiled: March 18, 2004Publication date: November 4, 2010Inventors: Kazuaki Sakurai, Masahiko Kawashima, Yutaka Matsuki, Shigeru Ueda, Mamoru Takahashi
-
Publication number: 20100273148Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for bladder and other types of cancer. In certain embodiments, BTMs or UBTMs can accumulate in the urine, and detection of UBTM family members can be an effective diagnostic approach. In some embodiments, quantitative PCR methods have advantages over microarray methods. In other embodiments, detection and quantification of a plurality of BTMs or UBTMs can increase the sensitivity and specificity of detection of bladder cancer, and therefore provides methods for determining the stage and type of bladder cancer. Kits provide easy, convenient ways for carrying out the methods of this invention.Type: ApplicationFiled: July 22, 2005Publication date: October 28, 2010Inventors: Parry John Guilford, Natalie Jane Kerr, Robert Craig Pollock
-
Publication number: 20100273171Abstract: Aspects of the present invention concern the identification of several methods to analyze the genes that are modulated in normal human bronchial epithelial (NHBE) cells after exposure to cigarette smoke condensates (CSC) or cigarette smoke (CS). Embodiments described herein include methods to identify a gene that is modulated in response to exposure to CSC or CS, methods to identify tobacco products that have a reduced potential to contribute to tobacco-related disease, methods to make tobacco products that have a reduced potential to contribute to a tobacco-related disease, methods to identify a subject's predilection to acquire a tobacco related disease, the use of particular genes as biomarkers for tobacco-related disease, and patterns of gene expression or genetic signatures that are unique to each particular tobacco product.Type: ApplicationFiled: April 29, 2010Publication date: October 28, 2010Applicant: VECTOR TOBACCO, INC.Inventors: Ellen D. Jorgensen, Anthony P. Albino, Wendy Jin
-
Patent number: 7820402Abstract: The immunoassay element for quantitatively analyzing an antigen by determining the change in enzymatic activity of an enzyme-labelled antigen or antibody caused by an immunological reaction. The immunoassay element comprises a substrate layer containing a non-diffusible substrate which forms a diffusible material in the presence of the labelling enzyme, and a reagent layer containing a fragmenting enzyme for further fragmenting the diffusible material into a lower molecular weight product. As the non-diffusible substrate, a substrate capable of reacting solely with the labelling enzyme and incapable of reacting the fragmenting enzyme is utilized. When an endo-active glucosidase is used as the labelling enzyme, and an exo-active glucosidase is used the fragmenting enzyme in the reagent layer, the non-diffusible substrate of the substrate layer is preferred to be an endo type selectively reactive substrate, which means a substrate having a reactivity specific to endo-active glucosidase.Type: GrantFiled: September 19, 2005Date of Patent: October 26, 2010Assignee: Fuji Photo Film Co., Ltd.Inventors: Yoshiki Sakaino, Hitomi Ito, Toshihiro Mori, Osamu Seshimoto, Toshihisa Ito, Yoshikazu Amano
-
Publication number: 20100267042Abstract: The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.Type: ApplicationFiled: April 1, 2010Publication date: October 21, 2010Inventors: Andrew L. Mellor, David H. Munn, Jeffrey Roberts Lee
-
Publication number: 20100267067Abstract: The present invention relates to a method for selecting at least one host cell secreting one or more active enzyme of interest, said method comprising the steps of: a) providing a growth medium comprising one or more synthase inhibitor, which inhibits the synthesis of at least one essential compound in the host cell, and further comprising one or more component, which in the presence of the one or more active enzyme of interest is converted into the at least one essential compound, thereby allowing the host cell to grow; b) cultivating the host cell in or on the growth medium of step (a); and c) selecting at least one host cell capable of growing in or on the growth medium of step (a), which host cell secretes one or more active enzyme of interest.Type: ApplicationFiled: November 26, 2008Publication date: October 21, 2010Applicant: Novozymes A/SInventor: Jesper Vind
-
Patent number: 7816075Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.Type: GrantFiled: July 11, 2005Date of Patent: October 19, 2010Assignees: Xenon Pharmaceuticals Inc., Wisconsin Alumni Research FoundationInventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
-
Patent number: 7807835Abstract: Compositions and methods for electrochemical detection of an analyte comprising a transition metal compound wherein M is a metallic element that can form a coordinate bond to nitrogen; R and R? are coordinated to M at their nitrogen atoms; L is a linking ligand; Z is chlorine or bromine; m can be from 1 to 6 and X is an anion, or combination of anions, that balances the charge m. Also provided are electrochemical tags and methods of detection.Type: GrantFiled: March 27, 2009Date of Patent: October 5, 2010Assignee: Agency for Science, Technology and ResearchInventors: Hong Xie, Zhiqiang Gao
-
Patent number: 7807402Abstract: A method and reagent for detecting the presence or amount of an analyte by a redox reaction and a fluorimetric determination, is disclosed. The reagent comprises a compound of the general formula Q-F as a redox indicator, wherein Q is a quencher group and F is a fluorophore group. The quencher group Q or/and the fluorophore group F can be reduced or oxidized, and the fluorescence can change depending on the reduction or oxidation.Type: GrantFiled: April 22, 2008Date of Patent: October 5, 2010Assignee: Roche Diagnostics Operations, Inc.Inventors: Carina Horn, Hans-Peter Josel, Juergen Spinke, Rupert Herrmann, Dieter Heindl
-
Patent number: 7807421Abstract: The present invention provides a transformed cell which is transformed by at least one gene of enzymes participating in biosynthesis of tetrahydrobiopterin and a process for the production of a biopterin compound using the same. In accordance with the present invention, the biopterin compound can be produced in large quantities in an industrial advantageous manner from less expensive materials.Type: GrantFiled: August 2, 2005Date of Patent: October 5, 2010Assignee: Asubio Pharma Co., Ltd.Inventors: Masayuki Yabuta, Kazuaki Furukawa, Nobue Miyamoto, Katsuhiko Yamamoto, Kazuhiro Ohsuye
-
Publication number: 20100248282Abstract: The present invention relates to a method for determining NO enzymatically and its use for the identification of substances which can modulate a nitric oxide synthase activity.Type: ApplicationFiled: June 9, 2010Publication date: September 30, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Frank BUETTNER
-
Patent number: 7803592Abstract: Substrate specificity for glucose of a glucose dehydrogenase having the amino acid sequence of SEQ ID NO: 13 is improved by substituting another amino acid residue for the amino acid residue at position 472 and/or 475.Type: GrantFiled: April 22, 2005Date of Patent: September 28, 2010Assignee: Arkray, Inc.Inventor: Hideaki Yamaoka
-
Publication number: 20100240069Abstract: The present invention relates to a high throughput assay for determining HIF 1? prolyl hydroxylation.Type: ApplicationFiled: March 18, 2009Publication date: September 23, 2010Applicant: Boehringer Ingelheim International GmbHInventors: John Alan Broadwater, Hnin Hnin Khine, Siqi Lin, Richard D. Schneiderman
-
Publication number: 20100240084Abstract: The protein MabA, also named protein FabG1, which is recombinant in a purified form, or the recombinant proteins derived from the protein MabA by mutation of at least one amino acid. The uses of proteins MabA, or recombinant proteins derived from protein MabA by mutation of at lease one amino acid, proteins and to the crystalloghraphis co-ordinates thereof, in terms of the implementation of methods for designing and screening ligands of these proteins, and advantageously, ligands inhibiting the enzymatic activity of these proteins.Type: ApplicationFiled: April 14, 2009Publication date: September 23, 2010Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1Inventors: Annaik QUEMARD, Gilles Labesse, Mamadou Daffe, Hedia Marrakchi, Dominique Douguet, Martin Cohen-Gonsaud, Stephanie Ducasse
-
Publication number: 20100233746Abstract: The present invention relates to a method for determining the systemic metabolic status of an organism in relation to inflammation and oxidative stress using a biological sample (Inflammation and Oxidative Stress Level Assay). This comprises detection and quantification of one or more derivatives of arachidonic acid (eicosanoids), linoleic acid and/or docosahexaenoic acid, preferably together with one or more oxidative stress parameters and/or with one or more analytes from other metabolite classes in parallel, as well as a kit adapted for carrying out such a method. Moreover, the invention relates to the biomarkers as employed in the method.Type: ApplicationFiled: May 30, 2008Publication date: September 16, 2010Inventors: Denise Sonntag, Therese Koal, Steven Lewis Ramsay, Sascha Dammeier, Klaus Michael Weinberger, Ines Unterwurzacher
-
Publication number: 20100233681Abstract: Disclosed is a method for cell storage on beads and subsequent utilisation of cryogenically stored cells in cellular assays.Type: ApplicationFiled: March 29, 2007Publication date: September 16, 2010Applicant: GE Healthcare UK LimitedInventors: Nicholas Thomas, Michael Kenneth Kenrick, Sharon Joanne Murathodzic
-
Patent number: 7797112Abstract: The present invention relates to a FabK (enoyl-acyl carrier protein reductase) protein derived from a Thermotoga maritima strain. In the present invention, the active site and the three-dimensional crystal structure of the protein are determined, a novel inhibitor against the FabK protein is screened and/or designed using the three-dimensional crystal structure thereof, and thereby developing a novel active compound, namely active-controlling material with excellent antibiotic activities against strains having a resistance to previous antibiotics.Type: GrantFiled: December 28, 2007Date of Patent: September 14, 2010Assignee: Korea Institute of Science and TechnologyInventors: Eunice Eun-Kyeong Kim, Byung Hak Ha
-
Patent number: 7794966Abstract: The present invention aims to enable highly reliable measurement of a glycated amine. A fructosyl amino acid oxidase (FAOD) is added to a sample to remove a non-analyte glycated amine that is present in the sample and different from an analyte glycated amine. Thereafter, a protease is added to the sample to degrade the analyte glycated amine, and the degradation product of the analyte glycated amine reacts with the FAOD that has already been added to the sample. By measuring this redox reaction, the amount of the analyte glycated amine can be measured.Type: GrantFiled: December 10, 2004Date of Patent: September 14, 2010Assignee: Arkray, Inc.Inventor: Kaoru Hirai
-
Publication number: 20100227353Abstract: The invention relates to a colorimetric method for detecting bacterial or fungal pathogens by detecting peptidoglycan or (1-3)-?-D-glucan in a sample.Type: ApplicationFiled: October 6, 2009Publication date: September 9, 2010Applicant: Immunetics, Inc.Inventors: Victor Kovalenko, Andrew E. Levin
-
Publication number: 20100227345Abstract: An aqueous enzyme based sensor comprising one or more enzymes and at least one indicator compound capable of indicating a reaction of at least one of the enzymes with at least one target analyte, wherein the enzyme and the indicator are capable of being delivered, preferably by being sprayed, to a surface having the target analyte without sampling the surface. An aqueous enzyme based sensor is provided that is capable of detecting an enzyme specific substrate as the analyte. This aqueous enzyme based sensor further comprises of one or more enzyme specific substrates in which the sensor detects enzyme inhibition. The aqueous enzyme based sensor optionally comprises one or more of a light scattering additive(s), an adhesive polymer(s), a protein stabilizer(s), a protein stabilizing sugar(s), a surfactant(s), and a solvent(s), and combinations thereof. A dispensing system and a method of detecting a target chemical on a surface without sampling the surface is provided.Type: ApplicationFiled: August 9, 2006Publication date: September 9, 2010Inventors: Keith E. LeJuene, Jennifer A. Bacior, Jason A. Berberich, Markus Erbeldinger, Bhalchandra Shripad Lele
-
Publication number: 20100227344Abstract: This invention relates to assays for detecting and measuring ADP. In particular, this invention provides homogeneous luminescent assays that detect ADP generation and measures ADP accumulation based on enzymatic coupling reactions. The assays of the present invention can be applied to all types of kinases and other ADP-generating enzymes, are antibody free, beads free, radioisotope free, and compatible with commonly used kinase buffers.Type: ApplicationFiled: November 12, 2008Publication date: September 9, 2010Applicant: GENEWIZ INC.Inventors: Zhong-Ping Sun, Shihong Li, Conrad Leung, Guo-Juan Liao
-
Publication number: 20100227355Abstract: Biological reagent compositions with improved sensitivity to the concentration of blood glucose in patient samples for use in measuring systems and methods. The reagent compositions comprise a glucose oxidoreductase enzyme, a flavin nucleoside coenzyme and a mediator formulation. The mediator formulation comprises at least one electroactive organic molecule and at least one coordination complex.Type: ApplicationFiled: March 15, 2010Publication date: September 9, 2010Applicant: Home Diagnostics, Inc.Inventors: Douglas E. Bell, Michele Albino
-
Publication number: 20100227354Abstract: The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.Type: ApplicationFiled: March 8, 2010Publication date: September 9, 2010Inventors: Rikard Holmdahl, Peter Olofsson
-
Patent number: 7790408Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.Type: GrantFiled: August 1, 2005Date of Patent: September 7, 2010Assignee: Wisconsin Alumni Research FoundationInventors: James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
-
Publication number: 20100221764Abstract: The present invention relates to an enzyme substrate for detecting nitroreductase activity of formula (I) below: in which X is S, NX1, O or NX1-CO; R1 is nothing or a substituent selected from Cl, CH3, Br, F, I, alkyl, aryl and carboxyl; R2 is nothing or a substituent selected from Cl, O—CH2—O, O—CH3, F, diethylenediamine-CH3, NR3R4, Br, I, alkyl, aryl, carboxyl, NO2 and R3 and R4 are independently H or an alkyl group containing from 1 to 4 carbon atoms; and X1 is selected from H, CH3, C2H4Ph, OH, alkyl and aryl.Type: ApplicationFiled: May 29, 2008Publication date: September 2, 2010Applicant: BIOMERIEUXInventors: Olivier Fabrega, Arthur James, Vindhya Lakshika Salwatura, Sylvain Orenga, Stephen Stanforth
-
Patent number: 7785850Abstract: The present invention relates to a process for heterologous expression and large-scale production of functionally active enzyme trypanothione reductase of Leishmania donovani in prokaryotic system.Type: GrantFiled: November 23, 2004Date of Patent: August 31, 2010Assignee: Council of Scientific and Industrial ResearchInventors: Neena Goyal, Mukul Kumar Mittal
-
Patent number: 7785822Abstract: The present invention provides methods for the detection of biliverdin in birds (avian species) and reptiles.Type: GrantFiled: August 27, 2003Date of Patent: August 31, 2010Assignee: University of Georgia Research Foundation, Inc.Inventors: Christopher Gregory, Branson W. Ritchie
-
Publication number: 20100216832Abstract: The present invention provides a method for assaying oxygenase activity, the method comprising monitoring oxygenase activity of FTO.Type: ApplicationFiled: June 20, 2008Publication date: August 26, 2010Inventors: Frances Mary Ashcroft, Christopher Paul Ponting, Thomas Gerken, Christopher Joseph Schofield
-
Publication number: 20100206746Abstract: A multi-layer pad that is adapted to be used in determining an analyte concentration is disclosed. The multi-layer pad includes a first layer, a second layer, and a third layer. The first layer includes an enzyme wherein the enzyme is adapted to assist in determining the analyte concentration. The second layer is attached to a first surface of the first layer. The second layer is made of a skin-conforming material. The third layer is attached to a second surface of the first layer wherein the first layer is located between the second layer and the third layer. It is contemplated that the multi-layer pad may also be a two layer system.Type: ApplicationFiled: May 30, 2007Publication date: August 19, 2010Applicant: Bayer HealthCare, LLCInventors: Boru Zhu, Mihailo V. Rebec, Pamela J. Burson
-
Publication number: 20100205690Abstract: The present invention disclosed herein provides a method for producing a plant with increased yield as compared to a corresponding wild type plant comprising increasing or generating one or more activities in a plant or a part thereof. The present invention further relates to nucleic acids enhancing or improving one or more traits of a transgenic plant, and cells, progenies, seeds and pollen derived from such plants or parts, as well as methods of making and methods of using such plant cell(s) or plant(s), progenies, seed(s) or pollen. Particularly, said improved trait(s) are manifested in an increased yield, preferably by improving one or more yield-related trait(s), e.g. low temperature tolerance.Type: ApplicationFiled: September 19, 2008Publication date: August 12, 2010Applicant: BASF Plant Science GmbHInventors: Oliver Bläsing, Piotr Puzio, Oliver Thimm, Gerhard Potzdam, Hardy Schön
-
Publication number: 20100203567Abstract: The invention provides methods and detection kits for detecting extended spectrum ?-lactamase producers (ESBLs). The kits typically comprise a carrier containing: a)at least one sugar; b) at least one antibiotic for killing Gram positive bacteria; c) at least one antifungal compound; d) a mixture of cefpodoxime and at least one additional antibiotic for killing Gram negative bacteria, and/or a mixture of cefotaxime and ceftazidime; and e) a pH indicator. The methods and kits can be used to by non-specialist health professionals to give rapid results at relatively low cost.Type: ApplicationFiled: March 17, 2008Publication date: August 12, 2010Inventors: Natalie Michelle Mitchell, Guduru Gopal Rao, James Wong
-
Publication number: 20100203563Abstract: This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress.Type: ApplicationFiled: April 4, 2008Publication date: August 12, 2010Inventor: Sárka O. Southern
-
Patent number: 7772007Abstract: An assay device and method for measuring the concentration of LDL-associated cholesterol in a blood-fluid sample are described. The method employs selective precipitation of VLDL and chylomicrons and immunoseparation of HDL from a blood fluid sample. The assay device allows the assay to be performed entirely in a flow strip format.Type: GrantFiled: March 31, 2005Date of Patent: August 10, 2010Assignee: Cholestech CorporationInventors: Jeffrey E. Shindelman, Thomas E. Worthy, Ronald M. Jones, George E. Withers, III
-
Publication number: 20100196459Abstract: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.Type: ApplicationFiled: November 23, 2009Publication date: August 5, 2010Inventor: Elizabeth Shanahan-Prendergast
-
Publication number: 20100196942Abstract: Novel, sensitive and specific markers for diagnostics and monitoring of liver injuries, including, but not limited to ischemic liver damage, are provided. This includes identification several enzymes of arginine/urea/nitric oxide cycle, sulfuration enzymes and spectrin breakdown related products, among others.Type: ApplicationFiled: January 12, 2010Publication date: August 5, 2010Applicants: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., BANYAN BIOMARKERS, INC.Inventors: STANISLAV I. SVETLOV, RONALD L. HAYES, KA-WANG (KEVIN) WANG, MONIKA OLI
-
Publication number: 20100197519Abstract: Methods for the evolution of NADPH specific ketol-acid reductoisomerase enzymes to acquire NADH specificity are provided. Specific mutant ketol-acid reductoisomerase enzymes isolated from Pseudomonas that have undergone co-factor switching to utilize NADH are described.Type: ApplicationFiled: December 15, 2009Publication date: August 5, 2010Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventors: Yougen Li, Der-Ing Liao, Mark J. Nelson, Daniel P. Okeefe
-
Publication number: 20100190196Abstract: A novel D-serine quantification method that can overcome various disadvantages of a conventional D-serine quantification method; a novel enzyme that can be used in the D-serine quantification method; a gene encoding the enzyme; and the like. Specifically, a novel D-serine dehydratase including (a) a protein having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a protein having an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 1 and having a D-serine dehydratase activity; and a D-serine quantification method including the steps of reacting a sample with the enzyme, quantifying ammonia or pyruvic acid produced by the reaction, and calculating the amount of D-serine in the sample based on a value produced by the quantification.Type: ApplicationFiled: October 16, 2007Publication date: July 29, 2010Applicant: National University Corporation Nagoya UniversityInventors: Tohru Yoshimura, Tomokazu Ito
-
Patent number: 7754470Abstract: Compositions and methods are provided for bioremediation of toxic metals.Type: GrantFiled: December 20, 2006Date of Patent: July 13, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: A. C. Matin, Yoram Barak, David F. Ackerley
-
Publication number: 20100173342Abstract: The present invention relates to a biomarker and a method for determining an oxidative stress level in a biological sample, which employs co-factor-dependent oxidative stress parameters, as well as a kit adapted for carrying out such a method. Preferably the co-factor is tetrahydrobiopterin.Type: ApplicationFiled: May 30, 2008Publication date: July 8, 2010Inventor: Klaus Michael WEINBERGER
-
Publication number: 20100168118Abstract: The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the amount of the selected polypeptide expressed by a reference cancer, wherein the polypeptide includes a member of folate pathways within cells and may include at least one of reduced folate carrier-1 enzyme (RFC-1), dihydrofolate reductase (DHFR), folylpoly-gamma-glutamate synthetase (FPGS), thymidylate synthase (TS), ?-glutamyl hydrolase (GGH), and glycinamide ribonucleotide formyltransferase (GARFT). The present invention also relates to the use of 10-propargyl-10-deazaminopterin in the treatment of multiple myeloma.Type: ApplicationFiled: December 14, 2009Publication date: July 1, 2010Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Owen A. O'Connor, Francis Sirotnak
-
Publication number: 20100167297Abstract: The present invention relates to a method for predicting the Time to Progression (TTP) of non small cell lung carcinoma (NSCLC) patients treated with chemotherapy, based on the detecting the levels of expression of thioredoxin (TRX) in a biological sample of the patient, or based on simultaneously detecting the expression levels of thioredoxin and the methylation status of the 14-3-3?gene.Type: ApplicationFiled: May 9, 2008Publication date: July 1, 2010Inventors: Rafael Rosell Costa, Miguel Tarón Roca